Related Experiment Videos
Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group
Insights
A mass screening system using the vanillylmandelic acid test effectively detects neuroblastoma in infants. This early detection significantly improves prognosis for affected children, with a high survival rate observed in the screened population.
Area of Science:
- Pediatric Oncology
- Public Health Screening
- Biochemical Diagnostics
Background:
- Neuroblastoma is a common childhood cancer.
- Early detection is crucial for improving patient outcomes.
- Existing screening methods have limitations.
Purpose of the Study:
- To evaluate a mass screening system for early neuroblastoma detection in infants.
- To assess the incidence of neuroblastoma in a large infant cohort.
- To determine the impact of early detection on prognosis.
Main Methods:
- Development and implementation of a mass screening system in eight districts in Japan.
- Utilized the vanillylmandelic acid (VMA) test for neuroblastoma detection.
- Screened 281,939 infants aged 6 months.
Main Results:
- Identified 16 cases of neuroblastoma, yielding an incidence of 1 in 17,621 infants.
- 15 out of 16 diagnosed infants survived.
- One infant died one month post-surgery, highlighting the critical nature of timely intervention.
Conclusions:
- The vanillylmandelic acid mass screening system is effective for early neuroblastoma detection in infants.
- Infant neuroblastoma screening can significantly improve survival rates.
- This system offers a promising approach to enhance prognosis for infants diagnosed with neuroblastoma.
Abstract:
A mass screening system for the early detection by means of a vanillylmandelic acid test of neuroblastoma in 6-month-old infants in Japan has been developed in eight districts. 16 of the 281 939 infants screened by this test had neuroblastoma, equivalent to a very high incidence of 1 in 17 621. 15 of the 16 children with neuroblastoma are alive; the other child died 1 month after surgery. This mass screening system for neuroblastoma used in infancy can help to improve prognosis in infants with this malignant disorder.